Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVERY for influenza or community-acquired pneumonia in hospitalized adults
2023-507441-29-00Phase 3Authorised
- Sponsor
- University of Oxford
- Start
- Feb 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of oseltamivir, hydrocortisone, prednisolone, dexamethasone and baloxavir marboxil in influenza and community-acquired pneumonia (CAP) (3 arms), sponsored by University of Oxford. Primary endpoints: 28-day all-cause mortality and Time to discharge alive from hospital within 28 days (influenza only). Planned start Feb 2024; status: authorised.
02
Drugs
oseltamivirhydrocortisoneprednisolonedexamethasonebaloxavir marboxil
03
Conditions
influenzacommunity-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2023-507441-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507441-29-00.